The focus of this study is the in vivo delivery of expression plasmids to produce glucocerebrosidase to treat Gaucher disease. Current efforts at gene therapy for hematopoietic disorders such as Gaucher disease have primarily focused on the use of retroviral vectors targeted to hematopoietic stem cells, which would then result in expression in mature monocyte that are produced. This approach has been greatly limited by the inability to transduce a significant fraction of hematopoietic stem cells. Therefore, the approach proposed in this proposal represents a completely different direction which would not have limitation of retroviral vector targeting to stem cells. Systemic delivery of plasmids complexed to cationic lipids may be able to introduce the GC gene into macrophages throughout the RE system and express GC enzyme in a way that it will be properly localized in the cell. The key questions which will need to be addressed are: 1) the percentages of relevant cells that can be transduced, 2) the quantitative level of expression achieved in appropriate target cells, 3) the duration of expression, 4) any toxic effects from introduction of plasmid/lipid complexes into the bloodstream or from ectopic expression of GC, and 5) the ability to repeat the procedure if expression is transient. The study has three specific aims: 1. Maximize the amount and duration of human glucocerebrosidase gene expression in blood monocytes and tissue macrophages of mice after cationic liposome-mediated in vivo gene delivery. 2. Target the delivery and expression of the glucocerebrosidase gene to monocytes and macrophages in animals, using ligand-based and/or promoter-based targeting. 3. Identify and minimize treatment-related systemic toxicity. The overall goal is to develop safe and effective methods for targeted delivery and expression of the human glucocerebrosidase gene in vivo. This is an essential step toward successful gene therapy for Gaucher disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK049550-04
Application #
2905727
Study Section
Medical Biochemistry Study Section (MEDB)
Program Officer
Mckeon, Catherine T
Project Start
1996-09-21
Project End
2000-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
California Pacific Medical Center Research Institute
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94107
Tache, Yvette; Brunnhuber, Stefan (2008) From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases. Ann N Y Acad Sci 1148:29-41
Yu, W H; Kashani-Sabet, M; Liggitt, D et al. (1999) Topical gene delivery to murine skin. J Invest Dermatol 112:370-5
Gaensler, K M; Tu, G; Bruch, S et al. (1999) Fetal gene transfer by transuterine injection of cationic liposome-DNA complexes. Nat Biotechnol 17:1188-92
Meuli-Simmen, C; Liu, Y; Yeo, T T et al. (1999) Gene expression along the cerebral-spinal axis after regional gene delivery. Hum Gene Ther 10:2689-700
Mounkes, L C; Zhong, W; Cipres-Palacin, G et al. (1998) Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 273:26164-70
Liu, Y; Mounkes, L C; Liggitt, H D et al. (1997) Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 15:167-73